Analyst puts pressure on Advanced Tissue

Advanced Tissue Sciences Inc. (ATIS) shares Friday plummeted 26 percent on 10.5 million shares traded when Morgan Stanley analyst Eric Hecht downgraded ATIS to "neutral" from "strong buy" after concluding that the company's Dermagraft-Ulcer trial data in diabetic foot ulcers are less robust than he had believed.

In addition, he said, overall trial

Read the full 533 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE